Should Men with Prior CVD be Treated Preferentially with a GnRH Antagonist?

Talazoparib plus enzalutamide appears to improve the objective response rate vs enzalutamide plus placebo among patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair mutations in the phase 3 TALAPRO-2 study.

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

According to an expert from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, radium-223 shows positive efficacy and safety findings for patients with metastatic castration-resistant prostate cancer.

Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.

The treatment discontinuation rate was 30.4% for darolutamide, 40.8% for enzalutamide, and 46.0% for apalutamide among patients with nonmetastatic prostate cancer, according to a recent analysis.

Patients with BRCA-mutated metastatic castration-resistant prostate cancer can now receive treatment with olaparib plus abiraterone/prednisone or prednisolone following the combination’s approval by the FDA.